Pune based Mylab Discovery Solutions has tied up with Dharwad-based Shilpa Biologicals (a 100 percent subsidiary of Shilpa Medicare Ltd) to produce the Covid-19 vaccine at Dharwad. The manufacturing is expected to start by March-2022.
The tie-up Starting with the Covid-19 vaccine manufacturing opportunity plans to strengthen the relationship by expanding the product portfolio in various other areas including various biosimilars, other vaccines & diagnostics.
Shilpa Biologicals will utilize its integrated R&D cum Manufacturing facility in Dharwad spanning over 11 acres, to cater to these requirements.
The first vaccine project under this long-term partnership is currently under the final evaluation phase and the manufacturing is expected to start soon.
Vinay Konaje, Managing Director of Shilpa Biologicals said, “We have deep expertise in R&D driven manufacturing of complex vaccines and biologicals at a scale that can serve the world.
Together with Mylab, we aim to create products that can serve Global markets and establish Market leadership.” he added.
Sujit Jain, Director, Corporate strategy, Mylab said, “ Our strategy to offer value-driven innovation helped us disrupt the diagnostics market in India. Combining Shilpa’s expertise with our strength, Mylab can create significant value with companion diagnostics.”
Hasmukh Rawal, Managing Director, Mylab Discovery Solutions, said “Our vision is to develop a complete ecosystem around the health of a patient. We want to ensure that from a provider to a patient all should get a fair value in the system.”
For this to happen, the current models of care have to change and it is only possible to do with an integrated approach from testing to the treatment of the patients.
“At Mylab, we are driven by the strong conviction that our technology would bring significant and affordable benefits to human health. We aim to provide life-saving solutions for people worldwide,” he added.
Source: Express Healthcare